Evidence map›Paper›PMID 31420967›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2020

Trends in deceased donor liver enzymes prior to transplant: The impact on graft selection and outcomes.

Melissa G Kaltenbach, Michael O Harhay, Peter L Abt, David S Goldberg

Abstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Donor Evaluation Protocol for Live and Deceased Donors.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Melissa G KaltenbachDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0003-0124-6670
Michael O HarhayDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Peter L AbtDivision of Transplantation, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
David S GoldbergDivision of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida.ORCID 0000-0002-1465-0691

Funding

CLINICAL EPIDEMIOLOGY TRAINING IN GASTROENTEROLOGYT32DK007740 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI James D Lewis · 1997 to 2026
$9.2M
Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantationR01DK120561 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI GOLDBERG, DAVID SETH · 2019 to 2023
$2.7M
Improving the measurement and analysis of long-term, patient-centered outcomes following acute respiratory failureR00HL141678 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI HARHAY, MICHAEL OSCAR · 2020 to 2022
$747k
Improving the measurement and analysis of long-term, patient-centered outcomes following acute respiratory failureK99HL141678 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI HARHAY, MICHAEL OSCAR · 2018 to 2019
$214k
NHLBI NIH HHS K99 HL141678NHLBI NIH HHS R00 HL141678NIDDK NIH HHS R01 DK120561NIDDK NIH HHS T32 DK007740
6 · The paper itself

Abstract

We sought to characterize the trend in alanine aminotransferase elevations prior to transplant and the impact on the pattern of enzyme elevations on organ utilization and graft function. We performed a retrospective cohort study of UNOS data on all deceased donors between 2007 and 2016. Serum alanine aminotransferase (ALT) was categorized into six study groups with peak ALT < 499, 500-749, 750-999, 1000-1999, 2000-2999, and >3000 IU/L. The change from peak ALT to terminal ALT prior to transplant was categorized as no change/increasing at time transplant, 0.1-9.9%, 10-24.9%, 25-49.9%, 50-74.9% and >75% change. In multivariable models evaluating liver utilization, the interaction between peak ALT and percent change in ALT was most pronounced at the highest peak ALT levels, where liver utilization varied markedly as a function of percentage drop from peak to terminal ALT. There was no increased risk of graft failure based on peak ALT. Markers of ischemic liver injury and recovery are significantly associated with liver utilization, yet among transplanted livers they were not associated with graft outcomes and may represent an area to expand the donor pool.

Indexed as

Graft SurvivalAdultDonor SelectionFemaleFollow-Up StudiesGraft RejectionHumansLiver DiseasesLiver TransplantationMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsTissue DonorsTransaminasesTransaminasesclinical research/practicedonors and donation: deceasedgraft survivalliver allograft function/dysfunctionliver transplantation/hepatology

Identifiers

PMID31420967
PMCPMC6940531

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.